SUSAN  BLANEY  to  Infant, Newborn
                            
                            
                                This is a "connection" page, showing publications  SUSAN  BLANEY  has written about  Infant, Newborn.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.044
         
        
        
     
 
    
        
        - 
            Current pharmacological treatment approaches to central nervous system leukaemia. Drugs. 1991 May; 41(5):702-16.
            
            
                Score: 0.009
            
         
        
        - 
            Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Williston Park). 1991 May; 5(5):107-16; discussion 123, 127.
            
            
                Score: 0.009
            
         
        
        - 
            A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):577-80.
            
            
                Score: 0.007
            
         
        
        - 
            Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20; 25(21):3137-43.
            
            
                Score: 0.007
            
         
        
        - 
            Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007 May; 59(6):847-53.
            
            
                Score: 0.006
            
         
        
        - 
            Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005 Jan; 19(1):34-8.
            
            
                Score: 0.006